Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 99

Sort by

Sort Order Select

Journal Articles

Optimal MRD-Based Endpoint in the Setting of Upfront Quadruplets (QUADs) to Support Response-Adapted Treatment Cessation in Newly Diagnosed Multiple Myeloma (NDMM)

Smith Giri, Binod Dhakal, Natalie Callander, Eva Medvedova, Kelly Godby, Susan Bal, Gayathri Ravi, Saurabh Chhabra, Rebecca W. Silbermann, Luciano J. Costa

Blood (2024) 144 (Supplement 1): 257.

https://doi.org/10.1182/blood-2024-205611

Published: 2024

Journal Articles

Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study

Blood (2024) 144 (Supplement 1): 256.

https://doi.org/10.1182/blood-2024-199374

Published: 2024

Journal Articles

Application of Stem Cell Boost for Immune Effector Cell Associated Hematotoxicity (ICAHT) Following BCMA Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Multiple Myeloma (MM)

Blood (2024) 144 (Supplement 1): 254.

https://doi.org/10.1182/blood-2024-210725

Published: 2024

Journal Articles

Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma

Doris K. Hansen, Lauren C. Peres, Danai Dima, Alicia Richards, Leyla O. Shune, Aimaz Afrough, Shonali Midha, Binod Dhakal, Mehmet H. Kocoglu, Shebli Atrash, Chris Ferreri, Omar Castaneda, James A Davis, Evguenia Ouchveridze, Joseph P. McGuirk, Charlotte B Wagner, Radhika Bansal, Patrick Costello, Kinaya Smith, Alex Lieberman-Cribbin, Gabriel De Avila, Sneha Purvey, Hitomi Hosoya, Lekha Mikkilineni, Laura B. Oswald, Gurbakhash Kaur, Oren Pasvolsky, Mahmoud R. Gaballa, Megan M Herr, Peter A. Forsberg, Murali Janakiram, Myo Htut, Sireesha Asoori, Nilesh Kalariya, Hamza Hashmi, Ran Reshef, Douglas W Sborov, Omar Nadeem, Faiz Anwer, Jack Khouri, Shahzad Raza, Djordje Atanackovic, Melissa Alsina, Ciara Louise Freeman, Frederick L. Locke, Peter M. Voorhees, Larry D Anderson, Jr., Shambavi Richard, Thomas Martin, Yi Lin, Krina K. Patel, Surbhi Sidana

Blood (2024) 144 (Supplement 1): 936.

https://doi.org/10.1182/blood-2024-194390

Published: 2024

Journal Articles

Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial

Blood (2024) 144 (Supplement 1): 1031.

https://doi.org/10.1182/blood-2024-198499

Published: 2024

Journal Articles

Talquetamab Bridging: Paving the Way to B-Cell Maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2024) 144 (Supplement 1): 931.

https://doi.org/10.1182/blood-2024-202017

Published: 2024

Journal Articles

Genome-Wide Association Study Identifies Novel Loci Associated with Survival in Multiple Myeloma

Remy Lee, Shahram Arsang-Jang, Anita D'Souza, Binod Dhakal, Siegfried Janz, Jing Dong

Blood (2024) 144 (Supplement 1): 4719.

https://doi.org/10.1182/blood-2024-201795

Published: 2024

Journal Articles

Efficacy of Stem Cell Boost (SCB) for Chimeric Antigen Receptor T Cell (CAR-T)-Related Hematologic Toxicity in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)- a Multi-Center Real World Experience

Blood (2024) 144 (Supplement 1): 4712.

https://doi.org/10.1182/blood-2024-204257

Published: 2024

Journal Articles

MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma (NDMM)- Master-2 Trial

Blood (2024) 144 (Supplement 1): 2000.1.

https://doi.org/10.1182/blood-2024-200210

Published: 2024

Journal Articles

Comparative Effectiveness of Ciltacabtagene Autoleucel from the Cartitude-4 Trial Vs Real-World Physician's Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma - an Updated Overall Survival Analysis

Blood (2024) 144 (Supplement 1): 7089.

https://doi.org/10.1182/blood-2024-205383

Published: 2024

Journal Articles

Efficacy of Carvykti in Cartitude-4 Versus Alternative Treatments from Daratumumab Clinical Trials for the Treatment of Patients with Lenalidomide-Refractory Multiple Myeloma

Michel Delforge, Irit Avivi Mazza, Maria- Victoria Mateos, Kristina Carlson, Keqin Qi, João Mendes, Seina Lee, Jordan M. Schecter, William Deraedt, Carolina Lonardi, Ana Slaughter, Diana Chen, Man Zhao, Kaitlyn Connors, Nitin Patel, Erika Florendo, Hermann Einsele, Binod Dhakal, Wilfried Roeloffzen

Blood (2024) 144 (Supplement 1): 7085.

https://doi.org/10.1182/blood-2024-201606

Published: 2024

Journal Articles

Systemic Review and Meta-Analysis of Safety and Efficacy of Bispecific Antibodies Among Older Adults with Multiple Myeloma

Elham Nasrollahi, Hafsa M Gundroo, Becky Alford, Ciare Louise Freeman, Binod Dhakal, Ravi Narra, Marcelo C. Pasquini, Anita D'Souza, Meera Mohan, Rahul Mhaskar, Othman Salim Akhtar

Blood (2024) 144 (Supplement 1): 6921.

https://doi.org/10.1182/blood-2024-204029

Published: 2024

Journal Articles

Chimeric Antigen Receptor T Cells (CAR-T) Vs. Bispecific Antibody (BsAb) Against B-Cell Maturation Antigen (BCMA) in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): A Systematic Review and Metaanalysis

Hayley Vandenboom, Aniko Szabo, Othman S Akhtar, Ravi Narra, Meera Mohan, Anita D'Souza, Marcelo C. Pasquini, Binod Dhakal

Blood (2024) 144 (Supplement 1): 6911.

https://doi.org/10.1182/blood-2024-200442

Published: 2024

Journal Articles

The Efficacy of Teclistamab in Multiple Myeloma Patients with Secondary Plasma Cell Leukemia

Asis Shrestha, Sharmilan Thanendrarajan, Aishee Bag, Binod Dhakal, Maurizio Zangari, Samer Al Hadidi, Suzanne Lentzsch, Frits van Rhee, Anita D'Souza, Rajshekhar Chakraborty, Nishi Shah, Mansi R. Shah, Meera Mohan, Carolina Schinke

Blood (2024) 144 (Supplement 1): 6994.

https://doi.org/10.1182/blood-2024-210478

Published: 2024

Journal Articles

Real-World Patient Characteristics and Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Receiving Teclistamab across Community Oncology Practices in the US

Blood (2024) 144 (Supplement 1): 7843.

https://doi.org/10.1182/blood-2024-208708

Published: 2024

Journal Articles

Real-World Patient Characteristics and Outcomes in Patients with High-Risk Cytogenetic Relapsed or Refractory Multiple Myeloma Receiving Teclistamab across Community Oncology Practices in the US

Blood (2024) 144 (Supplement 1): 7854.

https://doi.org/10.1182/blood-2024-210841

Published: 2024

Journal Articles

CD47-CD138 Bispecific Antibody Exhibits Selective Targeting of Multiple Myeloma

Maday Galeana Figueroa, Kishan Nyati, Tarang Sharma, Binod Dhakal, Meera Mohan, Parameswaran N. Hari, Sabarinath Venniyil Radhakrishnan

Blood (2024) 144 (Supplement 1): 4812.

https://doi.org/10.1182/blood-2024-208382

Published: 2024

Journal Articles

Activation-Inducible Bispecific BCMA-CD24 CAR-T Cells Precisely and Safely Control Multiple Myeloma Growth

Fumou Sun, Jing Dong, Peiman Hematti, Siegfried Janz, Binod Dhakal

Blood (2024) 144 (Supplement 1): 4791.

https://doi.org/10.1182/blood-2024-205476

Published: 2024

Journal Articles

Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium

Blood (2024) 144 (Supplement 1): 3765.

https://doi.org/10.1182/blood-2024-199609

Published: 2024

Journal Articles

Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma

Binod Dhakal, Hang Quach, Phoebe Joy Ho, Andrew Spencer, Mark A. Schroeder, Peter Tan, Tara Cochrane, Hanlon Sia, Jeffrey A. Zonder, Camille Martinet, Dominique Duchesne, Andrew Garton, Vinu Menon, Beata Holkova, Cyril Konto, Lida Pacaud, Dickran Kazandjian

Blood (2024) 144 (Supplement 1): 3364.

https://doi.org/10.1182/blood-2024-209952

Published: 2024

NARROW

Optimal MRD-Based Endpoint in the Setting of Upfront Quadruplets (QUADs) to Support Response-Adapted Treatment Cessation in Newly Diagnosed Multiple Myeloma (NDMM)

Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study

Application of Stem Cell Boost for Immune Effector Cell Associated Hematotoxicity (ICAHT) Following BCMA Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Multiple Myeloma (MM)

Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma

Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial

Talquetamab Bridging: Paving the Way to B-Cell Maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)

Genome-Wide Association Study Identifies Novel Loci Associated with Survival in Multiple Myeloma

Efficacy of Stem Cell Boost (SCB) for Chimeric Antigen Receptor T Cell (CAR-T)-Related Hematologic Toxicity in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)- a Multi-Center Real World Experience

MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma (NDMM)- Master-2 Trial

Comparative Effectiveness of Ciltacabtagene Autoleucel from the Cartitude-4 Trial Vs Real-World Physician's Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma - an Updated Overall Survival Analysis

Efficacy of Carvykti in Cartitude-4 Versus Alternative Treatments from Daratumumab Clinical Trials for the Treatment of Patients with Lenalidomide-Refractory Multiple Myeloma

Systemic Review and Meta-Analysis of Safety and Efficacy of Bispecific Antibodies Among Older Adults with Multiple Myeloma

Chimeric Antigen Receptor T Cells (CAR-T) Vs. Bispecific Antibody (BsAb) Against B-Cell Maturation Antigen (BCMA) in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): A Systematic Review and Metaanalysis

The Efficacy of Teclistamab in Multiple Myeloma Patients with Secondary Plasma Cell Leukemia

Real-World Patient Characteristics and Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Receiving Teclistamab across Community Oncology Practices in the US

Real-World Patient Characteristics and Outcomes in Patients with High-Risk Cytogenetic Relapsed or Refractory Multiple Myeloma Receiving Teclistamab across Community Oncology Practices in the US

CD47-CD138 Bispecific Antibody Exhibits Selective Targeting of Multiple Myeloma

Activation-Inducible Bispecific BCMA-CD24 CAR-T Cells Precisely and Safely Control Multiple Myeloma Growth

Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium

Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only